Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: A project of Kyushu University Liver Disease Study

Table 1 Baseline characteristics of 318 patients with chronic HBV infection treated with lamivudine (mean± SD)

Characteristics	Cirrhosis		P
	No	Yes
	n = 216	n = 102
Number of men (%)	154 (71.3)	77 (75.5)	0.5168
Age (yr)	45.0 ± 11.1	53.7 ± 9.7	< 0.0001
Number with 35 yr old and over (%)	173 (80.1)	98 (96.1)	0.0003
ALT (IU/L)	320.9 ± 503.3	101.5 ± 95.4	< 0.0001
Total bilirubin (mg/dL)	1.2 ± 1.3	1.4 ± 1.3	0.188
Albumin (g/dL)	4.0 ± 0.4	3.5 ± 0.6	< 0.0001
Platelet count (mean ± SD) (x104/μL)	16.2 ± 5.3	9.8 ± 4.4	< 0.0001
Number of HBeAg positivity (%)	119 (55.1)	54 (52.9)	0.8112
HBV-DNA1	6.8 ± 1.3	6.6 ± 1.2	0.1344
Lamivudine treatment (mo)	20.2 ± 8.9	21.8 ± 9.7	0.1429

ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; SD, standard deviation ¹Logarithmic transformed copies/mL.